NVO vs LLY
Novo Nordisk A/S vs Eli Lilly and Company — AI-powered side-by-side comparison
| Metric | NVO | LLY |
|---|---|---|
| AI Score | 56 | 63 |
| Price | $49.48 | $1,188.57 |
| P/E Ratio | 11.75× | 45.52× |
| ROE | 66.4% | 101.3% |
| Revenue Growth YoY | 8.1% | 47.4% |
| Gross Margin | 81.8% | 82.8% |
| Debt / Equity | 0.67× | 1.60× |
| Dividend Yield | 3.7% | 0.6% |
| RSI (14) | 65.6 | 51.0 |
| Beta | 1.8569 | 0.5022 |
| Expected Upside | +25.9% | — |
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
NVO Full Analysis
LLY Full Analysis